Merck releases Vioxx, Arcoxia data

Late Monday, MRK presented data from the APPROVe study of Vioxx rofecoxib -- the trial that prompted MRK to pull the COX-2 inhibitor from the market last

Read the full 275 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE